

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7304484

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
TOSHIHIDE KURIHARA	04/21/2022
YUSAKU KATADA	04/21/2022
KAZUO TSUBOTA	04/18/2022
HIDEKI KANDORI	04/21/2022
RECEIVING PARTY DATA	
Name:	RESTORE VISION INC.
Street Address:	15TH FLOOR, TORANOMON HILLS BUSINESS TOWER
Internal Address:	1-17-1, TORANOMON, MINATO-KU
City:	TOKYO
State/Country:	JAPAN
Postal Code:	1056415
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17731976
CORRESPONDENCE DATA	
Fax Number:	(646)219-6229
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6469732500
Email:	helen.hu@hglaw.com
Correspondent Name:	HALEY GUILIANO LLP
Address Line 1:	75 BROAD STREET
Address Line 2:	SUITE 1000
Address Line 4:	NEW YORK, NEW YORK 10004
ATTORNEY DOCKET NUMBER:	000373-0002-302
NAME OF SUBMITTER:	HELEN HU
SIGNATURE:	/Helen Hu/
DATE SIGNED:	04/28/2022
Total Attachments: 8	

source=000373-0002-302 Executed Assignment#page1.tif
source=000373-0002-302 Executed Assignment#page2.tif
source=000373-0002-302 Executed Assignment#page3.tif
source=000373-0002-302 Executed Assignment#page4.tif
source=000373-0002-302 Executed Assignment#page5.tif
source=000373-0002-302 Executed Assignment#page6.tif
source=000373-0002-302 Executed Assignment#page7.tif
source=000373-0002-302 Executed Assignment#page8.tif

CONFIRMATORY ASSIGNMENT

WHEREAS, we, **TOSHIHIDE KURIHARA, YUSAKU KATADA, KAZUO TSUBOTA**, and **HIDEKI KANDORI**, have invented one or more of the inventions described in the following applications (together “Applications”):

- (1) United States Non-Provisional Application No. * **17/642,923**, to be filed on* **March 14, 2022**, and entitled **“NUCLEIC ACID CONSTRUCT THAT ENCODES CHIMERIC RHODOPSIN”**;
- (2) International Patent Application, filed under the Patent Cooperation Treaty in the Japanese Receiving Office (RO/JP) on **September 11, 2020** assigned serial number **PCT/JP2020/034543** and entitled: **“NUCLEIC ACID CONSTRUCT THAT ENCODES CHIMERIC RHODOPSIN”**; and designating all PCT member states and regional offices, including Albania (AL), Algeria (DZ), Angola (AO), Antigua & Barbuda (AG), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Bahrain (BH), Barbados (BB), Belarus (BY), Belgium (BE), Belize (BZ), Benin (BJ), Bosnia and Herzegovina (BA), Botswana (BW), Brazil (BR), Bulgaria (BG), Brunei Darussalam (BN), Burkina Faso (BF), Cambodia (KH), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), Chile (CL), China (CN), Colombia (CO), Comoros (KM), Congo (CG), Costa Rica (CR), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czechia (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Djibouti (DJ), Dominica (DM), Dominican Republic (DO), Ecuador (EC), Egypt (EG), El Salvador (SV), Equatorial Guinea (GQ), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Greece (GR), Grenada (GD), Guatemala (GT), Guinea (GN), Guinea Bissau (GW), Honduras (HN), Hungary (HU), Iceland (IS), India (IN), Indonesia (ID), Ireland (IE), Islamic Republic of Iran (IR), Israel (IL), Italy (IT), Japan (JP), Jordan (JO), Kazakhstan (KZ), Kenya (KE), Kuwait (KW), Kyrgyzstan (KG), Lao People's Democratic Republic (LA), Latvia (LV), Lesotho (LS), Liberia (LR), Libya (LY), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), former Yugoslav Republic of Macedonia (MK), Malawi (MW), Malaysia (MY), Mali (ML), Malta (MT), Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Montenegro (ME), Morocco (MA), Mozambique (MZ), Namibia (NA), Netherlands (NL), New Zealand (NZ), Nicaragua (NI), Niger (NE), Nigeria (NG), Norway (NO), Oman (OM), Panama (PA), Papua New Guinea (PG), Peru (PE), the Philippines (PH), Poland (PL), Portugal (PT), Qatar (QA), Republic of Korea (KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU), Rwanda (RW), Saint Lucia (LC), Saint Kitts and Nevis (KN), Saint Vincent and the Grenadines (VC), Samoa (WS), San Marino (SM), São Tomé and

* I hereby authorize Haley Guiliano LLP to insert in this instrument the Application number and filing date of said Applications when Haley Guiliano LLP is officially notified thereof

Príncipe (ST), Saudi Arabia (SA), Senegal (SN), Serbia (RS), Seychelles (SC), Sierra Leone (SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland (CH), Syrian Arab Republic (SY), Tajikistan (TJ), United Republic of Tanzania (TZ), Togo (TG), Thailand (TH), Trinidad and Tobago (TT), Tunisia (TN), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab Emirates (AE), United Kingdom (GB), United States of America (US), Uzbekistan (UZ), Viet Nam (VN), Zambia (ZM) and Zimbabwe (ZW), and all other PCT member countries and regional offices;

WHEREAS, **Restore Vision Inc.**, (hereinafter "ASSIGNEE"), a corporation having an office and a place of business at **15th Floor, Toranomon Hills Business Tower, 1-17-1, Toranomon, Minato-ku, Tokyo 1056415, Japan**, has acquired my entire right, title and interest in the Applications in accordance with agreements duly entered into with me;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, including consideration of one Japanese Yen (¥1.00), the receipt of which is hereby acknowledged, I confirm that I have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, my entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said Applications (and any and all of the invention(s) described therein) and all patent applications that may be filed claiming the benefit to and/or priority to those Applications, including any continuation, continuation-in-part, division and foreign counterparts thereof, and any substitute applications therefor, and any patents which may issue thereon, or resulting from the national or regional phase of the above-identified International Patent Application in any country of the world, and any reissues and revivals of the same, (together with said Applications "applications and patents") and including the right to claim priority under any applicable statute, treaty or convention based on said Applications or the invention(s) therein; said inventions(s), right of priority, applications and patents to be held and enjoyed by said ASSIGNEE for its own use and that of its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by me had this assignment not been made. I also hereby convey all rights arising under or pursuant to any and all international

agreements, treaties or laws relating to the protection of industrial property by filing any such applications, all choses in action pertaining to the applications and patents including the right to sue for and collect damages and other recoveries for past infringement thereof, all rights to initiate proceedings before government and administrative bodies, and all files, records and other materials arising from the prosecution, exploitation, or defense of rights and registrations pertaining to the applications and patents. I hereby acknowledge that this assignment, being of my entire right, title and interest in and to said invention(s), applications and patents, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such patents to ASSIGNEE for its own name as ASSIGNEE of my entire right, title and interest therein;

AND, I hereby further have agreed and agree for myself and my executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid right of priority, invention(s), applications and patents to said ASSIGNEE, its successors, assigns and legal representatives, including the execution of applications for patents in the United States and all foreign countries, and the execution of substitute, reissue, divisional, continuation, continuation-in-part or revival applications and preliminary or other statements and the giving of testimony in any interference, derivation or other proceeding in which said invention(s) or the applications and/or patents directed thereto may be involved;

AND, I do hereby authorize and request the Commissioner of Patents of the United States and the respective patent offices in all foreign countries to issue such patents as shall be granted upon said Applications or applications based thereon or claiming right of priority thereto, to said ASSIGNEE, its successors, assigns, and legal representatives.

000373-0002-301

Inventor 
TOSHIHIDE KURIHARA

Date: 4/21/2022

Address: c/o School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku,
Tokyo 1608582, Japan


000373-0002-301

Inventor *Yusaku Katada*
YUSAKU KATADA

Date: Apr. 21. 2022

Address: c/o School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku,
Tokyo 1608582, Japan

000373-0002-301

Inventor 
KAZUO TSUBOTA

Date: Apr 18, 2022

Address: c/o School of Medicine, Keio University, 35, Shinanomachi, Shinjuku-ku,
Tokyo 1608582, Japan

000373-0002-301

Inventor Hideki Kandori
HIDEKI KANDORI


Date: April 21, 2022

Address: c/o Nagoya Institute of Technology, 29, Aza Kiichi, Gokiso-cho, Showa-ku, Nagoya-shi, Aichi 4668555, Japan

000373-0002-301

ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Confirmatory Assignment on behalf of **Restore Vision Inc.**

By: 
Name: Yusaku Katada
Title: President & CEO

Date: Apr. 21. 2022